BR-01T is under clinical development by Brise Pharmaceuticals and currently in Phase I for Chronic Low Back Pain (CLBP). According to GlobalData, Phase I drugs for Chronic Low Back Pain (CLBP) have a 95% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BR-01T’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BR-01T overview

The therapeutic candidate is under development for the treatment of an chronic low back pain. It is administered through parenteral route as injection. It acts by targeting tropomyosin receptor kinase A (Trk A).

Brise Pharmaceuticals overview

Brise Pharmaceuticals is a company that operates within the pharmaceuticals and healthcare industry, specifically focusing on the therapy area of central nervous system pain. It specializes in developing and manufacturing treatments for pain management. The company is headquartered in Shanghai City, Shanghai, China.

For a complete picture of BR-01T’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.